AS-1763 in Patients With Previously Treated CLL/SLL or Non-Hodgkin Lymphoma
Conditions: B-cell Malignancy; Chronic Lymphocytic Leukemia; Small Lymphocytic Lymphoma; Waldenstrom Macroglobulinemia; Mantle Cell Lymphoma; Marginal Zone Lymphoma; Follicular Lymphoma; Non-Hodgkin Lymphoma Intervention: Drug: AS-1763 Sponsor: Carna Biosciences, Inc. Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
More News: Cancer & Oncology | Leukemia | Lymphoma | Macroglobulinemia | Non-Hodgkin's Lymphoma | Research | Waldenstrom's Macroglobulinemia